RxDoctor Payments Data

Larry Greenbaum, MD

Rheumatology · Greenwood, INNPI 1316927072

Payments from drug & device makers

$2,150in general payments, 2019–2025

Across 30 payments — averaging $71.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$2K
  • AbbVie$289
  • Amgen$103
  • E.r. Squibb & Sons, L.L.C.$48
  • Novartis$18
  • Pfizer$12

What the payments were for

  • Consulting fees$1,68078%
  • Food & beverage$44020%
  • Education$301%

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.2$1,680
AbbVie18$289
Amgen5$103
E.r. Squibb & Sons, L.L.C.3$48
Novartis1$18
Pfizer1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,150 in reported general payments places this provider in the 40th percentile of 106 rheumatology providers in Indiana.

See all rheumatology providers in Indiana

Medicare billing

Part B allowed, 2024
$129,192
Medicare patients
616
Services billed
5,837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab130$952,924
RinvoqUpadacitinib47$337,509
Enbrel SureclickEtanercept40$288,502
Xeljanz XrTofacitinib Citrate39$265,100
EnbrelEtanercept28$221,445
Cosentyx Sensoready (2 Pens)Secukinumab24$173,125
Cimzia (2 Pack)Certolizumab Pegol15$113,100
Cosentyx Unoready PenSecukinumab11$79,798
ActemraTocilizumab13$62,308
RybelsusSemaglutide15$20,442
MethotrexateMethotrexate Sodium826$17,024
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen550$16,348
Hydroxychloroquine Sulfate449$13,914
Sulfasalazine233$5,580
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen147$5,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$289$337,50947 claims
AmgenEnbrel$103$221,44528 claims
Genentech, Inc.Actemra$1,680$62,30813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 106 rheumatology providers in Indiana.

Other rheumatology in Greenwood

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →